New blood test able to detect 50 cancer types

31 Mar 2020

Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.

GRAIL, a healthcare company whose mission is to detect cancer early, has devised a blood test that can "detect more than 50 cancer types across all stages".

New blood test able to detect 50 cancer types

The company's foundational Circulating Cell-free Genome Atlas (CCGA) study included more than 15,000 participants — some with, some without diagnosed cancer.

Data for the company's multi-cancer early detection blood test, which have been published in Annals of Oncology, demonstrate the technology has a very low false positive rate of less than 1%, through a single blood draw.

When a cancer signal is detected, the test can also identify where the cancer is located in the body with 93% accuracy.

Currently, the majority of deadly cancers do not have guideline-recommended screening tests available, and as a result, most cancers are detected too late, after they have progressed to late stages when chances of survival are much lower. When cancer is diagnosed after it has spread, the 5-year cancer-specific survival rate is 21%, compared with 89% when the cancer is diagnosed early and still localized.

Alex Aravanis, Chief Scientific Officer and Head of R&D, and a co-founder of GRAIL has described this as a "seminal moment in the field of cancer detection". He said: "We’ve built what we believe to be one of the largest clinical study programs ever conducted in genomic medicine."

The impact of early detection on cancer mortality can be modeled using data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. GRAIL has also published new data modeling the most recent SEER statistics in Cancer Epidemiology, Biomarkers & Prevention, showing that if all cancers currently diagnosed at stage IV could be diagnosed earlier, evenly distributed across stages I-III, cancer deaths could fall by 24%.

Clinical studies are still ongoing and additional findings will be made publicly available.

Read More

Related news

HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Bio-Rad launches anti-certolizumab pegol antibodies

Bio-Rad launches anti-certolizumab pegol antibodies

5 May 2020

Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

Read more 
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

13 Apr 2020

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

Read more 
AstraZeneca incredibly excited by lung cancer treatment trial

AstraZeneca "incredibly excited" by lung cancer treatment trial

13 Apr 2020

Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.

Read more 
German pharma companies are meeting the corona stress test

German pharma companies are meeting the corona "stress test"

7 Apr 2020

The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.

Read more 
World’s leading biobanks join a global network to advance personalized healthcare research

World’s leading biobanks join a global network to advance personalized healthcare research

6 Apr 2020

The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

Read more 
Servier strengthens its R&D pipeline with Symphogen acquisition

Servier strengthens its R&D pipeline with Symphogen acquisition

6 Apr 2020

Symphogen becomes the antibody center of excellence within Servier.

Read more